Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Kindstar Globalgene (康圣环球) IPO: Fairly Valued for a Questionable Moat

Kindstar Globalgene (康圣环球) Pre-IPO: Financial and Valuation Update

Kindstar (康圣环球) Pre-IPO: Is It Worth the Premium?

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Kindstar Globalgene Technology / Equity Capital Markets

Kindstar Globalgene raised HKD 2,054 million (USD 264m) from its global offering and will list on the Hong Kong Stock Exchange on Friday, July 16th.
In our previous note, we discussed Kindstar's business segment. The company has a strong footprint in the hematology test segment with the majority of its revenue is derived from the hematological tests, particularly for lymphoma and myeloma-related diseases. The company is relatively weak in other areas such as oncology and maternity related businesses. We think the company can continue to grow the existing pie of hematological tests for which the public hospitals do not want to invest in the test equipment and processes but it will be challenging for the company to expand the business into the area where public hospitals are willing to invest in. We think the company has a decent line-up of investors but there is still a lack of international healthcare investors. The management's experience is also decent. 
In this note, we look at the updates since our last note. The demand for the deal is strong from the retail side but not so strong on the institution side. With its valuation higher than leading ICL peer, we do not expect a strong debut performance.

Kindstar Globalgene raised HKD 2,054 million (USD 264m) from its global offering and will list on the Hong Kong Stock Exchange on Friday, July 16th.
In our previous note, we discussed Kindstar's business segment. The company has a strong footprint in the hematology test segment with the majority of its revenue is derived from the hematological tests, particularly for lymphoma and myeloma-related diseases. The company is relatively weak in other areas such as oncology and maternity related businesses. We think the company can continue to grow the existing pie of hematological tests for which the public hospitals do not want to invest in the test equipment and processes but it will be challenging for the company to expand the business into the area where public hospitals are willing to invest in. We think the company has a decent line-up of investors but there is still a lack of international healthcare investors. The management's experience is also decent. 
In this note, we look at the updates since our last note. The demand for the deal is strong from the retail side but not so strong on the institution side. With its valuation higher than leading ICL peer, we do not expect a strong debut performance.

Kindstar (康圣环球) IPO Trading: Pattern of Demand Divergence